17/2/2020 Project Twenty21 - drugscience.org.

uk

Home Latest Project Twenty21

MEDICINAL CANNABIS

Project Twenty21
NOVEMBER 7 2019

Drug Science launched Europe’s rst and biggest national medical cannabis
registry, called Project Twenty21, on the 7th November 2019.

Project TWENTY21 will enrol 20,000 patients by the end of 2021, creating the
largest body of evidence for the effectiveness and tolerability of medical cannabis
– with an aim to demonstrate to policymakers that medical cannabis should be
as widely available, and affordable, as other approved medicines for patients who
would bene t from them.

It will also support prescribers across the country to feel con dent in providing
medical cannabis to patients. We hope that the ndings will make a powerful
case for NHS funding, by proving the favourable risk/bene t ratio of medical
cannabis in seven key identi ed conditions. In the rst instance, this real-world
registry will be targeting the following patients and situations, speci cally
focusing on those in which alternative treatment has failed:

Anxiety Disorder
Chronic Pain
Epilepsy
Multiple Sclerosis (MS)
Post Traumatic Stress Disorder (PTSD)
Substance Use Disorder (as a harm reduction strategy)
Tourette’s Syndrome

Treatment will be provided at a network of clinics across the UK which utilise

best-practice in medical cannabis treatment from recognised global leaders in
medical cannabis, including Canada and Australia.

If you are patient with one (or more) of the conditions named above, and wish
to hear more about Project Twenty21, please submit your name and email
address below.

https://drugscience.org.uk/project-twenty21/ 1/3
17/2/2020 Project Twenty21 - drugscience.org.uk

First Name

Last Name

E-mail address

By checking this box I consent to the use of my information provided to keep

me updated as to Drug Science content and news relating to the Twenty21 pilot
study. We will always treat your personal details with the utmost care and
respect.

Subscribe

PLEASE NOTE: Prescription of medical cannabis will remain the decision of the
provider, dependent on full clinical assessment and physician recommendation.
Drug Science takes no responsibility for clinical oversight.

If you are a GMC registered consultant psychiatrist, neurologist or pain

specialist and are interested in contributing to Project Twenty21 data collection
when prescribing medical cannabis to your patients, please email
prescribers@drugscience.org.uk. The primary objective of Project Twenty21 is to
develop a body of evidence using a real-world data (RWD) registry to document
ef cacy, safety, QALY, and patient reported outcomes with regards to medical
cannabis use.

Our Scienti c Oversight Board

https://drugscience.org.uk/project-twenty21/ 2/3
17/2/2020 Project Twenty21 - drugscience.org.uk

Keep up with developments in drug science

Reading, engaging with, and sharing our publications, papers and commentary gives evidence-based
science and policy the audience it needs and deserves.

Get Our Emails

Privacy Policy Terms and conditions

Get Our Emails
Cookie policy Contact

© 2020 Drug Science. All rights reserved

https://drugscience.org.uk/project-twenty21/ 3/3